Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Splash Beverage Group appoints new COO, invests in Avicanna and approves large equity plans

Splash Beverage Group named Michael Bondurant as COO and appointed Brady Cobb as interim CEO; both received salary- and performance-based bonus arrangements plus option grants (Cobb 925,000, Bondurant 800,000 options at $0.25). The board approved additional option awards for executives and considered a Strategic Transformation RSU plan that could cover up to 20% of diluted shares (about 8,373,000 shares), subject to shareholder approval and performance conditions. The company invested $217,479.24 in a private placement of Avicanna shares and warrants and is in discussions about potential further transactions with Avicanna. » More on de.investing.com
Avicanna reaches profitability in Q4 2025 despite stagnating revenues

Avicanna reports an adjusted EBITDA of CAD 310,000 for Q4 2025 and an improved gross margin of 53%, while 2025 revenue stagnated at CAD 25.5m. MyMedi.ca contributed 80% of revenue. Adjusted EBITDA for the full year remained a loss of CAD 300,000; the annual net loss fell to CAD 2.7m (improvement of 41%). Management and strategy will now focus on profitability, operational efficiency, product innovations (launch of Generation 3.0) and international expansion; revenue forecasts for 2026/2027 are USD 18.3m. » More on de.investing.com

Financials

In the last quarter, AVICANNA INC. had revenue of €3.48M and net profit of -€630.12K

(EUR)	June 2026	YoY
Revenue	3.48M	9.41%
Gross profit	1.85M	5.28%
Net profit	-630.12K	44.12%
EBITDA	-565.85K	79.15%

Fundamentals

Metric	Value
Market capitalization	€9.05M
Number of shares	134.38M
52-week high/low	€0.18 - €0.0535
Dividends	No
Beta	0.33
P/E ratio	-3.24
PEG ratio	0.05
P/B ratio	2.88
P/S ratio	0.56

Company profile

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.